These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 38050782

  • 1. Virtual platelet cross-matching as transfusion management for patients with immune platelet refractoriness.
    Bonet-Bub C, Blanco BP, de Oliveira TC, Sampaio TB, Gomes I, de Freitas Dutra V, Costa TH, Kutner JM.
    Vox Sang; 2024 Mar; 119(3):272-276. PubMed ID: 38050782
    [Abstract] [Full Text] [Related]

  • 2. [Establish a Graded Method to Avoid HLA Class I Antibodies Corresponding Antigen and Combining HLAMatchmaker Application in Improving the CCI Value after Platelet Transfusion for Patients with IPTR].
    Gao SQ, Xu YP, Luo CR, Li DC, Pen L, Liu T, Zou QC.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):242-249. PubMed ID: 38387929
    [Abstract] [Full Text] [Related]

  • 3. Determination in vivo viability of a transfused platelet product by corrected count increment and percentage platelet response.
    Thuku NW, Shikuku K, Mbugua A.
    Pan Afr Med J; 2017 Feb; 27():226. PubMed ID: 28979628
    [Abstract] [Full Text] [Related]

  • 4. [An evaluation of platelet transfusion response using HLA crossmatch-compatible donors in patients with platelet refractoriness].
    Hyun J, Lim YM, Park KD, Han BY, Kim YH, Han KS, Park MH.
    Korean J Lab Med; 2009 Oct; 29(5):481-9. PubMed ID: 19893359
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Diagnosis and treatment of immunological platelet refractoriness by histocompatibility.
    Fagundes IS, Franz JM, Jobim MS, Arend A, Merzoni J, Cardone JM, Gil B, Sekine L, Jobim LF.
    Hum Immunol; 2020 May; 81(5):197-201. PubMed ID: 32067841
    [Abstract] [Full Text] [Related]

  • 9. The use of a potential novel tool in virtual crossmatching for platelet transfusion in platelet refractoriness.
    Bub CB, Gonçalez AC, Barjas-Castro ML, Sousa LC, do Monte SJ, Castro V.
    Vox Sang; 2016 Jan; 110(1):70-8. PubMed ID: 26274830
    [Abstract] [Full Text] [Related]

  • 10. Human Leukocyte Antigen Class I Antibodies and Response to Platelet Transfusion in Patients Undergoing Liver Transplantation.
    Wong M, Narra R, Selim M, Zimmerman MA, Kim J, Padmanabhan A, Hong JC.
    J Surg Res; 2020 Nov; 255():99-105. PubMed ID: 32543385
    [Abstract] [Full Text] [Related]

  • 11. Cumulative donor-specific antibody threshold predicts platelet transfusion response in HLA-alloimmunized patients.
    Boothby AB, Tanner MK, Alswied A, Youngs D, Bribiesca Rodriguez J, Bikkani T, Cha N, Gernsheimer T, Gimferrer I, Hess JR, Sokol-Hessner L, Marivada S, Nash MG, Flegel WA, Vassallo RR, Stroncek DF, Tsang HC, Panch SR.
    Blood Adv; 2024 Sep 10; 8(17):4689-4699. PubMed ID: 39028936
    [Abstract] [Full Text] [Related]

  • 12. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients.
    Hogge DE, McConnell M, Jacobson C, Sutherland HJ, Benny WB, Massing BG.
    Transfusion; 1995 Aug 10; 35(8):645-52. PubMed ID: 7631404
    [Abstract] [Full Text] [Related]

  • 13. Identification of platelet refractoriness in oncohematologic patients.
    Ferreira AA, Zulli R, Soares S, Castro Vd, Moraes-Souza H.
    Clinics (Sao Paulo); 2011 Aug 10; 66(1):35-40. PubMed ID: 21437433
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.
    Wang J, Xia W, Deng J, Xu X, Shao Y, Ding H, Chen Y, Liu J, Chen D, Ye X, Santoso S.
    Transfus Med; 2018 Feb 10; 28(1):40-46. PubMed ID: 28516675
    [Abstract] [Full Text] [Related]

  • 17. How do I … manage the platelet transfusion-refractory patient?
    Juskewitch JE, Norgan AP, De Goey SR, Duellman PM, Wakefield LL, Gandhi MJ, Stubbs JR, Kreuter JD.
    Transfusion; 2017 Dec 10; 57(12):2828-2835. PubMed ID: 28960321
    [Abstract] [Full Text] [Related]

  • 18. Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the PLADO trial.
    Hess JR, Trachtenberg FL, Assmann SF, Triulzi DJ, Kaufman RM, Strauss RG, Granger S, Slichter SJ.
    Vox Sang; 2016 Oct 10; 111(3):281-291. PubMed ID: 27185561
    [Abstract] [Full Text] [Related]

  • 19. Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness.
    Saris A, Pavenski K.
    Transfus Med Rev; 2020 Oct 10; 34(4):250-257. PubMed ID: 33127210
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.